Celgene's Oral REVLIMID Plus Dexamethasone Given Approval to Treatment Patients with Newly Diagnosed Multiple Myeloma in Japan

By: via Benzinga
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that REVLIMID® ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.